Krishna Vaddi reports 13.15% Prelude Therapeutics (PRLD) stake in Schedule 13G/A

Rhea-AI Filing Summary

Prelude Therapeutics Inc. insider ownership update: Krishna Vaddi reported beneficial ownership of 6,745,647 shares of Prelude Therapeutics common stock, representing 13.15% of the class as of December 31, 2025. This includes directly held shares, stock options exercisable within 60 days, and shares held through Sidus Ventures, LLC and several trusts for which he is deemed to have beneficial ownership.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 6)

Prelude Therapeutics Inc

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

74065P101

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 74065P101

1

Names of Reporting Persons

Vaddi Krishna

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 6,745,647.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 6,745,647.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

6,745,647.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

13.15 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: (1) The aggregate amount beneficially owned by the Reporting Person consists of (i) 5,075,889 shares of voting common stock beneficially owned directly by the Reporting Person, consisting of (a) 1,999,296 shares of voting common stock and (b) 3,076,593 shares of voting common stock that are subject to options that are exercisable within 60 days of December 31, 2025, (ii) 142,553 shares of voting common stock held by Sidus Ventures, LLC, (iii) 423,655 shares of voting common stock held by Dolphin City Trust, (iv) 551,776 shares of voting common stock held by Blue Sky Trust and (v) 551,774 shares of voting common stock held by Brocade Trust. The Reporting Person is the manager of Sidus Ventures, LLC and may be deemed to have beneficial ownership over the securities held by Sidus Ventures, LLC. The Reporting Person is the beneficiary of Dolphin City Trust and may be deemed to have beneficial ownership over the securities held by Dolphin City Trust. The Reporting Person is the investment advisor for each of the Blue Sky Trust and the Brocade Trust, and may be deemed to have beneficial ownership over the securities held by each of the Blue Sky Trust and the Brocade Trust. (2) The percentage reported in row 11 is calculated in accordance with Rule 13d-3 based on the aggregate number of shares of common stock beneficially owned by the Reporting Person and an aggregate of 48,225,493 shares of voting common stock outstanding as of December 31, 2025, as reported by the Issuer to the Reporting Person, plus the number of shares of stock options held by the Reporting Person that are exercisable within 60 days of December 31, 2025, which are treated as converted into common stock only for the purpose of computing the percentage ownership of the Reporting Person.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Prelude Therapeutics Inc
(b)	Address of issuer's principal executive offices: 175 INNOVATION BOULEVARD, WILMINGTON, Delaware, 19805
Item 2.
(a)	Name of person filing: Krishna Vaddi (the "Reporting Person")
(b)	Address or principal business office or, if none, residence: The address of the principal business office of the Reporting Person is: c/o Prelude Therapeutics Incorporated 175 Innovation Boulevard Wilmington, Delaware 19805
(c)	Citizenship: United States
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP No.: 74065P101
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See Row 9 of cover page for each Reporting Person.
(b)	Percent of class: See Row 11 of cover page for each Reporting Person.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See Row 5 of cover page for each Reporting Person.
	(ii) Shared power to vote or to direct the vote: See Row 6 of cover page for each Reporting Person.
	(iii) Sole power to dispose or to direct the disposition of: See Row 7 of cover page for each Reporting Person.
	(iv) Shared power to dispose or to direct the disposition of: See Row 8 of cover page for each Reporting Person.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.	Certifications:
	Not Applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Vaddi Krishna

Signature:	/s/ Krishna Vaddi
Name/Title:	Krishna Vaddi
Date:	02/13/2026

FAQ

How many Prelude Therapeutics (PRLD) shares does Krishna Vaddi beneficially own?

Krishna Vaddi beneficially owns 6,745,647 shares of Prelude Therapeutics common stock. This total combines directly held shares, stock options exercisable within 60 days of December 31, 2025, and shares held through Sidus Ventures, LLC and several related trusts.

What percentage of Prelude Therapeutics (PRLD) does Krishna Vaddi own?

Krishna Vaddi owns 13.15% of Prelude Therapeutics’ common stock. This percentage is calculated under SEC Rule 13d-3 based on 48,225,493 outstanding shares as of December 31, 2025, plus his stock options exercisable within 60 days of that date.

How is Krishna Vaddi’s Prelude Therapeutics (PRLD) ownership structured?

His 6,745,647-share beneficial stake includes 5,075,889 shares directly (common stock and near-term exercisable options) and additional shares held by Sidus Ventures, LLC, Dolphin City Trust, Blue Sky Trust, and Brocade Trust, over which he is deemed to have beneficial ownership.

What role do options play in Krishna Vaddi’s PRLD ownership?

His direct beneficial ownership includes 3,076,593 shares of common stock underlying options exercisable within 60 days of December 31, 2025. Under SEC Rule 13d-3, these exercisable options are treated as converted into common stock when computing his ownership percentage.

How many Prelude Therapeutics (PRLD) shares were outstanding for this ownership calculation?

The ownership percentage uses 48,225,493 shares of Prelude Therapeutics voting common stock outstanding as of December 31, 2025. To calculate Krishna Vaddi’s 13.15% stake, the total also includes his stock options exercisable within 60 days of that date.

Does Krishna Vaddi have sole voting and dispositive power over his PRLD shares?

The filing reports 6,745,647 shares under sole voting power and sole dispositive power for Krishna Vaddi. It shows 0 shares under shared voting and shared dispositive power, indicating exclusive authority over voting and disposition for the reported holdings.

Which entities associated with Krishna Vaddi hold Prelude Therapeutics (PRLD) shares?

Associated holdings include 142,553 shares via Sidus Ventures, LLC, 423,655 shares via Dolphin City Trust, 551,776 shares via Blue Sky Trust, and 551,774 shares via Brocade Trust. Krishna Vaddi is deemed to have beneficial ownership over these entities’ share positions.